Ideas to shape the future of health - New Statesman conference

Brain Tumour Research

3 min read

For the second year running Brain Tumour Research attended the New Statesman Future of Healthcare conference.

There were panel discussions on improving patient outcomes through the life sciences, future-proofing UK health, and creating a more productive and resilient healthcare system

Helen Morgan MP, Liberal Democrat Spokesperson for Health and Social Care, said that the new Government had begun to address some of the issues affecting health and care services, but “more is needed, and it is needed now.”

Lord Bethell, Former Minister for Innovation, praised the Government for its rhetoric on health and called for a culture change within the health system. He noted that “the late stage doctrine has run its course”, and that a more proactive approach to healthcare is required.

George Freeman MP, former Minister for Science whom we met at Conservative Party Conference, said that data for cancers needs to flow better, there needs to be more democratised clinical trials, and that charities must play a much stronger role in achieving this. Mr Freeman added that the rare and less common cancer sector can “drive democratisation and digitalisation”.

Dr Samantha Dixon, Medical Director at Biogen, said that the “problems experienced by the rare disease sector are reflective of those across the system – but more acutely felt by rare conditions nevertheless.” Dr Dixon asked the Government to focus on creating a better regulatory environment, where the regulator can work at speed.

The afternoon keynote was an “In conversation with Victoria Atkins MP”, Shadow Secretary of State for Health and Social Care.

Her message to Government was “listen to charities”, and that their expertise is essential in the functioning of government.

She added that, as brain tumours are difficult to diagnose and to treat, charities such as Brain Tumour Research need to help Ministers to understand the benefits of good quality research.

Our Policy and Public Affairs Manager Thomas Brayford said: “The key take-aways from this year’s conference are that rare and less common cancers should be a priority for Government, as they can be a key UK strategic strength. Also, we need to see an improved drug regulatory environment, with timely access to medicines. These will help to change the story for brain tumour patients.”